About this episode
P.M. Edition for July 24. Today an FDA committee voted to increase access to six of seven peptides. Those are substances that haven’t undergone regulatory approval, but they’re promoted on social media and promise physical transformations like better skin. We hear from WSJ health and wellness reporter Alex Janin about what the vote means and whether it paves the way for a peptide gold rush. Plus, new tariffs went into effect today intended to combat forced labor, and President Trump also threatened new tariffs on the European Union. Journal trade and economic policy reporter Gavin Bade discusses the future of President Trump’s tariff agenda. And measles cases in the U.S. this year have already surpassed last year’s number, reaching a three-decade high. Alex Ossola hosts.
And for more on peptides, listen to our What’s News Sunday episode.
Sign up for the WSJ's free What's News newsletter.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
Get every episode summarized
Each time WSJ What’s News publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from WSJ What’s News
Fearing a Loss of Control, AI Bosses Call for Tech Slowdown
WSJ What’s News
Inside Pete Hegseth’s Pentagon Shake-Up
WSJ What’s News
What’s News in Markets: Amgen’s Prognosis, Quantum Boost, iPhone Makeover
WSJ What’s News
Inflation Held Steady in August, Pushing the Fed Towards a Rate Hike
WSJ What’s News